The chimeric antigen receptor T-cell therapy tisagenlecleucel has been approved for a second type of blood cancer; the National Institutes of Health has started recruiting individuals for a database that will include data on more than 1 million people; Kansas’ request to impose a 3-year lifetime limit on Medicaid benefits is testing just how open the Trump administration is to allowing states flexibility.
The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (sold as Kymriah by Novartis) has been approved for a second type of blood cancer. The new indication will allow tisagenlecleucel to compete directly with the other CAR T-cell therapy approved in cancer, axicabtagene ciloleucel (marketed as Yescarta by Gilead Science), reported Reuters. The new indication is for treatment of large B-cell lymphoma that has worsened despite 2 or more previous lines of therapy. Tisagenlecleucel was first approved in patients up to age 25 with acute lymphoblastic leukemia.
As part of the All of Us program, the National Institutes of Health (NIH) is recruiting individuals for a database that will include data on more than 1 million people. According to The Wall Street Journal, the effort is an attempt to understand the genetics of diseases and healthy aging. The database will be open to researchers and currently only adults are eligible to volunteer their data. NIH will also make efforts to recruit people who are often underrepresented in medical research.
Kansas’ request to impose a 3-year lifetime limit on Medicaid benefits is testing just how open the Trump administration is to allowing states flexibility. The administration planned to announce it had rejected the request, but canceled at the last minute, indicating internal disagreements, reported The Hill. Kansas’ request would drop people from the Medicaid program forever after they receive benefits for 3 years.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More